ClinicalTrials.gg
CompletedNCT03556007Updated Nov 18, 2023

A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)

A Phase 1 interventional study of LY3471851 and Placebo in Systemic Lupus Erythematosus, sponsored by Nektar Therapeutics. Completed at 14 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Nektar Therapeutics · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Aug 2019, 7 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 477 studies in Lupus Erythematosus, Systemic with a site in United States — 87 open to participants now, 127 under way, 28 of them phase 3. Lupus Erythematosus, Systemic · United States.

Enrollment
241st of 407
48 · median 70
Started
2018
with 28 others
Phase 1
104 of 477
24 open now
Registered
266th of 477
by date

Among the 477 studies in Lupus Erythematosus, Systemic with a site in United States, this one is the 241st largest by enrollment of the 407 interventional ones that give a count, is one of 29 that started in 2018, is one of 104 in phase 1, and was the 266th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

87 of the 477 studies in Lupus Erythematosus, Systemic with a site in United States are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 477 studies in Lupus Erythematosus, Systemic with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the safety and tolerability of a study drug known as LY3471851 in participants with SLE. The study will last about 79 days for each participant.

Read the detailed description

LY3471851 is a potential first-in-class therapeutic that may address an underlying immune system imbalance in people with many autoimmune conditions. It targets the interleukin (IL-2) receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells. By activating these cells, LY3471851 may act to bring the immune system back into balance.

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and immunologic effects of multiple doses of LY3471851 in participants with minimal to moderate SLE. The effects on SLE disease activity will also be evaluated. SLE participants will be randomized to receive multiple subcutaneous (SC) doses of LY3471851 or receive placebo. After receiving the last dose of LY3471851 or placebo, participants will be followed for an additional 50 days to evaluate safety, PK, pharmacodynamics (PD), and preliminary efficacy.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • T regulatory cells
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give written and comply with study procedures and requirements.
  • (BMI) between 18.0 and 32.0 kilograms per square meter (kg/m²).
  • Systolic blood pressure between 90 to 140 millimeters of mercury (mm Hg), diastolic blood pressure between 50 to 90 mm Hg, and resting heart rate between 40 to 100 beats per minute.
  • Diagnosis of adult SLE according to the 1997 ACR classification criteria for at least 6 months prior to signing the informed consent form (ICF).
  • Minimal to moderate SLE disease activity (active SLE clinical disease is not required for enrollment into the study and participants with severe SLE clinical disease activity, based on the evaluation of the investigator, should be excluded).
  • If a participant is taking oral prednisone (or prednisone equivalent) for their SLE, the dose must be less than or equal to (≤) 10 milligrams per day (mg/day) for a minimum of 8 weeks prior to screening. In addition, the dose of oral prednisone or prednisone equivalent the participant is taking must be stable for a minimum of 2 weeks prior to screening.
  • If a participant is taking any of the medications below for their SLE, the medication must have been administered for a minimum of 12 weeks prior to signing the ICF, and at a stable dose for a minimum of 8 weeks prior to signing the ICF:

    • Azathioprine ≤ 200 mg/day
    • Antimalarial (e.g., chloroquine, hydroxychloroquine, quinacrine)
    • Mycophenolate mofetil ≤ 2 grams per day (g/day) or mycophenolic acid ≤ 1.44 g/day
    • Oral, SC, or intramuscular methotrexate ≤ 15 milligrams per week (mg/week).
  • Willing and able to participate in the study for a duration of up to 4 months.
  • Willing and able to abstain from participating in another clinical study for a duration of up to 4 months.
  • Female participants will be non-pregnant, non-lactating, and either for at least 2 years, or surgically sterile for at least 3 months, or will agree to use double barrier from period prior to study enrollment until 5 months following the last dose received; women of must have a negative serum beta-human chorionic gonadotropin (β-hCG) test at screening and randomization prior to administration of product.
  • Male participants with female partners of childbearing potential must agree to use double barrier contraception during the study (until 5 months following the last dose received). Sperm donation is also restricted during the time-frame that males must be using double barrier contraception. This criterion may be waived for male participants who have had a vasectomy greater than (>) 6 months prior to enrollment.

Exclusion criteria

Exclusion Criteria:

Medical Conditions:

  • Current active bacterial, viral, or fungal infection.
  • Evidence of significant hematologic dysfunction.
  • Evidence of significant liver or kidney dysfunction.
  • History of, or current diagnosis of, a non SLE-related vasculitis syndrome.
  • Active severe or unstable neuropsychiatric SLE.
  • Active severe SLE-driven renal disease or history of severe active lupus nephritis with persisting proteinuria levels greater than 0.5 grams/24 hours.
  • Diagnosis (within 1 year of signing the ICF) of mixed connective tissue disease or any history of overlap syndromes of SLE.
  • History of, or current, inflammatory joint or skin disease other than SLE.
  • History of any non-SLE disease that has required treatment with oral or parenteral for more than 2 weeks within the last 24 weeks prior to signing the ICF.
  • Active tuberculosis (TB) on the basis of positive medical history or chest radiograph (OR) evidence of latent TB or by positive (or persistently indeterminate) Quantiferon-TB Gold or T-Spot test.
  • Known history of a primary immunodeficiency, splenectomy, or any underlying condition that predisposes the participant to infection.
  • Confirmed positive serology for , (Viral Hepatitis C Antibody Screen [anti-HCV]), or a positive result for (HIV) antibody screen.
  • Any severe herpes infection at any time prior to screening per judgement of the investigator.
  • History of opportunistic infection requiring hospitalization or intravenous antimicrobial treatment within 3 years prior to randomization.
  • History of major surgery within 12 weeks of screening or will require major surgery during the study.
  • Clinically significant electrocardiographic abnormalities.
  • History of any significant cardiovascular disease (e.g., myocardial infarction, congestive heart failure, uncontrolled hypertension, cerebrovascular accident), thrombotic episode, or any severe non-SLE medical illness within the previous 1 year.
  • History of cancer, apart from:

    • Squamous or basal cell carcinoma of the skin that has been successfully treated.
    • Cervical cancer in situ that has been successfully treated.

Medications:

  • Receipt of any product (small molecule or biologic agent) within 4 weeks or 5 half-lives prior to signing of the ICF, whichever is greater.
  • Receipt of belimumab in 6 months prior to screening.
  • History of treatment with rituximab or ocrelizumab (or other B cell depleting agent) within 6 months prior to screening. For participants who received their last treatment with rituximab or ocrelizumab more than 6 months earlier, evidence of significant and persisting low B cell levels in blood.
  • History of cytotoxic medications (e.g., cyclophosphamide) within preceding 12 months.
  • Receipt of any intra-articular, intramuscular, or intravenous (IV) glucocorticoids within 6 weeks prior to screening.
  • Receipt of blood products within 6 months prior to screening.

General:

  • Receipt of blood products within 6 months prior to screening and donation of blood or plasma to a blood bank or for a clinical study (except for screening of this study) within 28 days prior to screening.
  • Participants who have a history of organ or bone marrow transplant.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort 1 - 3 μg/kg LY3471851

    Participants received 3 microgram per kilogram (μg/kg) of LY3471851 or placebo on days 1, 15 and 29 by subcutaneous (SC) injection.

    Drug: LY3471851 · Drug: Placebo

  • Experimental
    Cohort 1 - 6 μg/kg LY3471851

    Participants received 6 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.

    Drug: LY3471851 · Drug: Placebo

  • Experimental
    Cohort 1 - 12 μg/kg LY3471851

    Participants received 12 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.

    Drug: LY3471851 · Drug: Placebo

  • Experimental
    Cohort 1 - 24 μg/kg LY3471851

    Participants received 24 μg/kg of LY3471851 or placebo on days 1, 15 and 29 by SC injection.

    Drug: LY3471851 · Drug: Placebo

Interventions

  • LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

    Also known as: NKTR-358

  • DrugPlacebo

    The placebo dosing solution is 0.9% sodium chloride for injection (USP).

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of LY3471851 - Number of Participants Experiencing Adverse Events

    Safety and tolerability of LY3471851 as assessed through collection of adverse events, serious adverse events, change in vital signs (body temperature, blood pressure, heart rate, rate of breathing and oxygen in blood); electrocardiograms (ECG); laboratory evaluations (hematology, chemistry, liver function and urine analysis).

    Time frame: Informed consent until last study visit (approximately 79 days after first dose of study drug)

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Drug Concentration - Time Curve from Zero to the End of Dosing Interval (i.e, 14 days past each dose) (AUC[0-Day 14]) of LY3471851

    PK measurement of AUC 0-Day 14

    Time frame: Baseline until 14 days after last dose (approximately 43 days after first dose of study drug)

  2. PK: Maximum Observed Drug Concentration (Cmax) of LY3471851 After First and Last Dose

    PK: Measurement of Cmax

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  3. PK: Time to Maximum Plasma Concentration (Tmax) of LY3471851

    PK: Measurement of Tmax

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  4. PK: Time to Decrease in Concentration of LY3471851 by Half (T1/2) Due to Elimination

    PK: Measurement of T1/2

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  5. Pharmacodynamics (PD): Measurement of Change in Number of Regulatory T Cells (Tregs) and Subsets of Tregs in Blood

    PD: Measurement of Change in Number of Regulatory T Cells (Tregs) and Subsets of Tregs in Blood

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  6. PD: Measurement Activity of Tregs

    PD: Measurement Activity of Tregs

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  7. PD: Measurement of Change in Number of Subsets of Conventional T Cells (Tcons) in Blood

    PD: Measurement of Change in Number of Subsets of Conventional T Cells

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  8. PD: Measurement of Change in Number of Natural Killer Cells (NK Cells) in Blood

    PD: Measurement of Change in Number of Natural Killer Cells (NK Cells) in Blood

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  9. PD: Measurement of Cytokines in Blood

    PD: Measurement of Cytokines in Blood

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  10. Change in Disease Activity (SLEDAI): Urine; Measurement of Hematuria, Pyuria, Urinary Casts, Creatinine, Protein

    Change in Disease Activity (SLEDAI): Urine; Measurement of Hematuria, Pyuria, Urinary Casts, Creatinine, Protein

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  11. Change in Disease Activity (SLEDAI): Blood: Measurement of Anti-dsDNA, Complement, White Blood Cells and Platelets

    Change in Disease Activity (SLEDAI): Blood: Measurement of Anti-dsDNA, Complement, White Blood Cells and Platelets

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  12. Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Physical Examination

    Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Physical Examination

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  13. Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Urine Analysis

    Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Urine Analysis

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  14. Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Blood Analysis

    Change in Disease Activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): Blood Analysis

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  15. Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Skin on the Body

    Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Skin on the Body

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  16. Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Mucous Membrane

    Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Mucous Membrane

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  17. Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Scalp

    Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Scalp

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  18. Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Hair Loss

    Change in Disease Activity (Cutaneous Lupus Erythematosus Disease Area Severity Index (CLASI): Evaluation of Hair Loss

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  19. Change in Disease Activity (Joint score): Evaluation of Tender Joints in the Body

    Change in Disease Activity (Joint score): Evaluation of Tender Joints in the Body

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

  20. Change in Disease Activity (Joint Score): Evaluation of Swollen Joints in the Body

    Change in Disease Activity (Joint Score): Evaluation of Swollen Joints in the Body

    Time frame: Baseline until last study visit (approximately 79 days after first dose of study drug)

07

Study locations

14 sites
  • Investigator Site - Anniston
    Anniston, Alabama 36207, United States
  • Investigator Site - La Jolla
    La Jolla, California 92037, United States
  • Investigator Site - Clearwater
    Clearwater, Florida 33765, United States
  • Investigator Site - Orlando
    Orlando, Florida 32806, United States
  • Investigator Site-Tampa
    Tampa, Florida 33603, United States
  • Investigator Site - Great Neck
    Great Neck, New York 11021, United States
  • Investigator Site- Wilmington
    Wilmington, North Carolina 28401, United States
  • Investigator Site - Middleburg Heights
    Middleburg Heights, Ohio 44130, United States
  • Investigator Site - Duncansville
    Duncansville, Pennsylvania 16635, United States
  • Investigator Site - Jackson
    Jackson, Tennessee 38305, United States
  • Investigator Site - Memphis
    Memphis, Tennessee 38119, United States
  • Investigator Site - Austin
    Austin, Texas 78745, United States
  • Investigator Site - Dallas
    Dallas, Texas 75231, United States
  • Investigator Site - Mesquite
    Mesquite, Texas 75150, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Aug 2019, 16 months.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's 16 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2018
First posted
Jun 14, 2018
StartActual
Apr 18, 2018
Primary completionActual
Aug 29, 2019
CompletionActual
Aug 29, 2019
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03556007
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
Apr 18, 2018
Primary completion
Aug 29, 2019
Completion
Aug 29, 2019
Last update
Nov 18, 2023

Study contacts

Study Director
study director · Nektar Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rezpegaldesleukin

Start the discussion